NCT03107208View on ClinicalTrials.gov

Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes

PHASE4CompletedINTERVENTIONAL
Enrollment

61

Participants

Timeline

Start Date

July 21, 2017

Primary Completion Date

March 13, 2021

Study Completion Date

March 13, 2021

Conditions
Diabetic KetoacidosisType 1 Diabetes Mellitus
Interventions
DRUG

Glargine

A dose of glargine (Lantus) will be given subcutaneously either early in the management of DKA (study group) or upon resolution of DKA (control group).

DEVICE

Continuous Glucose Monitor (Abbott FreeStyle Libre Pro)

All participants will be asked to wear a continuous glucose monitor (CGM) during the DKA and for a week following the DKA in order to better understand blood glucose control during DKA. This is an optional part of the study.

Trial Locations (1)

80045

Children's Hospital Colorado, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER

NCT03107208 - Early Glargine (Lantus) in DKA Management in Children With Type 1 Diabetes | Biotech Hunter | Biotech Hunter